Sign In
Buy CLVS
$0.151
+0 (+0%)
At Close: Apr 19, 2023
Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss
04:42pm, Monday, 08'th Aug 2022 Zacks Investment Research
Clovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts. CLVS faces the risk of a cash crunch.
Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss
02:18pm, Monday, 08'th Aug 2022
Clovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.
Why Clovis Oncology Stock Is Sinking Today
01:37pm, Monday, 08'th Aug 2022
The biotech's Q2 financial results are concerning investors today.
Clovis Oncology (CLVS) Reports Q2 Loss, Misses Revenue Estimates
01:15pm, Monday, 08'th Aug 2022 Zacks Investment Research
Clovis (CLVS) delivered earnings and revenue surprises of -2.38% and 15.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Is Clovis Oncology (CLVS) Stock Down 10% Today?
01:11pm, Monday, 08'th Aug 2022
Clovis Oncology (NASDAQ: CLVS ) stock is down more than 10% today after posting its second-quarter financial results. The biopharmaceutical company missed on revenue and profits, leading the way for t
Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q2 2022 Results - Earnings Call Transcript
12:42pm, Monday, 08'th Aug 2022
Clovis Oncology, Inc. (NASDAQ:CLVS ) Q2 2022 Earnings Conference Call August 8, 2022 8:30 AM ET Company Participants Anna Sussman - VP, IR Patrick Mahaffy - Co-Founder, CEO, President & Executive Dire
Will Clene Inc. (CLNN) Report Negative Q2 Earnings? What You Should Know
02:00pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Clene Inc. (CLNN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
02:01pm, Monday, 01'st Aug 2022 Zacks Investment Research
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
7 Penny Stocks to Buy Before the Bull Market Returns
08:30am, Monday, 01'st Aug 2022
In recent weeks, the stock market has stabilized after June's sell-off, but it may take time before bullishness makes a comeback. Plenty of uncertainty remains, including further interest rate hikes,
CORRECTING and REPLACING Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8
06:06pm, Wednesday, 20'th Jul 2022
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--First paragraph, second sentence of release should read: Clovis' senior management will host a conference call and live audio webcast at 8:30am ET to discuss
Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8
04:00pm, Wednesday, 20'th Jul 2022
BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2022 financial results and provide an update on its clinical development programs and r
Why Clovis Oncology Stock Trounced the Market Today
07:43pm, Tuesday, 19'th Jul 2022 The Motley Fool
Investors were cheered by news of a freshly signed supply deal.
Why Clovis Oncology Stock Trounced the Market Today
03:43pm, Tuesday, 19'th Jul 2022
Investors were cheered by news of a freshly signed supply deal.
Clovis Oncology (CLVS) Stock Pops 7% on Supply Agreement
12:17pm, Tuesday, 19'th Jul 2022
CLVS stock is rallying 7% after Clovis Oncology made a major deal with NorthStar Medical. Takeover speculation has swirled around Clovis.
Why Clovis Oncology Stock Went Into Retreat Mode This Week
01:53pm, Friday, 15'th Jul 2022 The Motley Fool
After a massive surge in its share price recently, Clovis Oncology has started to reverse course.
